Study of RP-6306 in Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2023-06-01

Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

• Phase: Phase 1

Details

• Lead Sponsor: Repare Therapeutics